Rivastigmine in frontotemporal dementia: an open-label study

Area of Science:

• Neuroscience
• Pharmacology
• Geriatrics

Background:

• Frontotemporal dementia (FTD) is a progressive neurodegenerative disorder characterized by behavioral and cognitive changes.
• Current treatment options for FTD are limited, with a focus on managing symptoms.

Purpose of the Study:

• To investigate the efficacy and tolerability of rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), in patients with probable FTD.
• To assess the impact of rivastigmine on behavioral disturbances, caregiver burden, and cognitive function over a 12-month period.

Main Methods:

• A preliminary, open-label study involving 20 patients (60-75 years) diagnosed with probable FTD.
• Participants received daily doses of rivastigmine ranging from 3-9 mg.
• A control group received antipsychotics, benzodiazepines, and selegiline (deprenyl). All patients completed a 12-month follow-up.

Main Results:

• Rivastigmine treatment was well-tolerated by FTD patients.
• Significant reductions in behavioral changes were observed, as measured by the Neuropsychiatric Inventory, Behavioral Pathology in Alzheimer's Disease Rating Scale, and Cornell Scale for Depression in Dementia.
• Caregiver burden decreased, indicated by reduced Relative Stress Scale scores. Executive functions stabilized, but cognition assessed by Mini-Mental State Examination did not improve.

Conclusions:

• Rivastigmine treatment led to reduced behavioral impairments and lessened caregiver burden in FTD patients after 12 months.
• The findings suggest that cholinesterase inhibitors like rivastigmine may be beneficial for managing behavioral symptoms in FTD.
• Further research into the use of cholinesterase inhibitors for FTD is warranted.